Elicio Therapeutics, Inc. (ELTX) Stock Price & Analysis

Elicio Therapeutics, Inc. (ELTX) fell 2.49% to USD 2.35 as of September 9, 2026 at 10:03 UTC, according to Nexqual real-time market data.

ELTX last closed at USD 2.41; the session ranged USD 2.34–2.46 on volume of 324,492 shares. Market capitalization is $61.76M, with a 52-week range of USD 2.34–16 (NCM). Source: Nexqual, September 9, 2026 at 10:03 UTC.

Key Statistics (as of September 9, 2026 at 10:03 UTC)

Technical Analysis (ELTX)

Nexqual's technical model rates ELTX "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 10:03 UTC.

Analyst Ratings (ELTX)

Wall Street analysts rate ELTX "None" based on 2 analysts, with a mean price target of USD 16.5 (range USD 10–23), per Nexqual as of September 9, 2026 at 10:03 UTC.

Earnings (ELTX)

Recent Earnings History

Source: Nexqual, September 9, 2026 at 10:03 UTC.

Financials & Fundamentals (ELTX)

Source: Nexqual, September 9, 2026 at 10:03 UTC.

Financial Health Score (ELTX)

Nexqual rates Elicio Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 9, 2026 at 10:03 UTC.

Ownership (ELTX)

Source: Nexqual, September 9, 2026 at 10:03 UTC.

Leadership (ELTX)

Elicio Therapeutics, Inc. is led by Robert T. Connelly (age 65), CEO, President & Director, per Nexqual as of September 9, 2026 at 10:03 UTC.

Major Backers & Investors (ELTX)

Notable institutional backers of Elicio Therapeutics, Inc. include Knoll Capital Management, LLC, Fidelity, Ikarian Capital, LLC, according to Nexqual as of September 9, 2026 at 10:03 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 9, 2026 at 10:03 UTC.

From Elicio Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• AMP Technology: Lymph node targeting via albumin hitchhiking Our proprietary AMP technology, and combined expertise in immunology and materials science, allows us to develop AMP immunotherapies capable of generating robust and differentiated immune responses.
• Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
• Our proprietary Amphiphile ("AMP") technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients.
• We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.

Partnerships

• We are evaluating opportunities to advance ELI-002 in clinical trials for CRC and other indications including in collaboration with other organizations. • Advance development of our internal pipeline, including ELI-007 and ELI-008, for additional oncology targets.
• Licensing, Collaboration and Partnership Agreements MIT License Agreement On January 27, 2016, we entered into an Exclusive Patent License Agreement with Massachusetts Institute of Technology ("MIT"), which has been amended from time to time (the "MIT License Agreement").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:03 UTC. This page is informational and not investment advice.